Publication
New Brunswick programs | COVID-19: Funding and financial relief programs for startups and small businesses
Author:
Canada | Publication | June 2020
A detailed table outlining the various programs available in New Brunswick are listed below. If you would like to discuss your eligibility for any of these programs, please do not hesitate to contact a member of our team.
- Atlantic Canada Opportunities Agency (ACOA)’s Atlantic Innovation Fund
- Propel Accelerator
- NB Small Business Emergency Working Capital Program
- Waiving Late Penalties on Property Taxes
- Deferring Interest and Principal Payments on Existing Loans
- Injecting Working Capital for Mid-to-Large Employers
- Community Investment Fund (CIF)
- WorkSafeNB
Atlantic Canada Opportunities Agency (ACOA)’s Atlantic Innovation Fund
Description | Eligibility | Application details |
---|---|---|
|
|
|
Propel Accelerator
Description | Eligibility | Application details |
---|---|---|
|
|
|
NB Small Business Emergency Working Capital Program
Description | Eligibility | Application details |
---|---|---|
|
|
|
Waiving Late Penalties on Property Taxes
Description | Eligibility | Application details |
---|---|---|
|
|
|
Deferring Interest and Principal Payments on Existing Loans
Description | Eligibility | Application details |
---|---|---|
|
|
|
Injecting Working Capital for Mid-to-Large Employers
Description | Eligibility | Application details |
---|---|---|
|
|
|
Community Investment Fund (CIF)
Description | Eligibility | Application details |
---|---|---|
|
|
|
WorkSafeNB
Description | Eligibility | Application details |
---|---|---|
|
|
|
Recent publications
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .